Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CDC42 | P60953 | 1/20 | 0.49 |
| ▸ | RB1 | P06400 | 8/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4157057 | 0.99 | CYP2D6 (0.56) | CYP2D6KCNH2CDC42RB1GAA | |
| SCHEMBL30455081 | 0.91 | CYP2D6 (0.70) | CYP2D6KCNH2CDC42RB1GAA | |
| SCHEMBL4191954 | 0.91 | CYP2D6 (0.70) | CYP2D6KCNH2CDC42RB1GAA | |
| SCHEMBL22135733 | 0.91 | CYP2D6 (0.70) | CYP2D6KCNH2CDC42RB1GAA | |
| Hydrochloric Acid SCHEMBL4160295 | 0.90 | CYP2D6 (0.69) | CYP2D6KCNH2CDC42RB1GAA | |
| SCHEMBL5447177 | 0.89 | CYP2D6 (0.55) | CYP2D6KCNH2CDC42RB1GAA | |
| SCHEMBL5461722 | 0.89 | BRD3 (0.49) | CYP2D6KCNH2CDC42RB1GAA | |
| SCHEMBL4201376 | 0.88 | CYP2D6 (0.65) | CYP2D6KCNH2CDC42RB1GAA | |
| Hydrochloric Acid SCHEMBL4165595 | 0.87 | CYP2D6 (0.64) | CYP2D6KCNH2CDC42RB1GAA | |
| SCHEMBL22135853 | 0.86 | RB1 (0.62) | CYP2D6CDC42RB1GAACASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658068-B1 | NOVEL CYCLOALKYL[B] CONDENSED INDOLES | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | claimed |
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170923-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | CYP2D6 994/4885KCNH2 4356/4885CDC42 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.